AIM Stock Summary and Trading Ideas (Aim Immunotech | AMEX:AIM)

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Aim Immunotech trades on the AMEX stock market under the symbol AIM.

As of April 3, 2025, AIM stock price was flat at $0.12 with 338,794 million shares trading.

AIM has a beta of 0.99, meaning it tends to be less sensitive to market movements. AIM has a correlation of 0.03 to the broad based SPY ETF.

AIM has a market cap of $8.09 million. This is considered a Sub-Micro Cap stock.

Last quarter Aim Immunotech reported $45,000 in Revenue and -$.10 earnings per share. This met revenue expectation and met earnings estimates .

In the last 3 years, AIM traded as high as $1.38 and as low as $.11.

The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF.

AIM has underperformed the market in the last year with a return of -73.8%, while the SPY ETF gained +4.8%. In the last 3 month period, AIM fell short of the market, returning -45.8%, while SPY returned -7.9%. However, in the most recent 2 weeks AIM has outperformed the stock market by returning -4.1%, while SPY returned -5.1%.

AIM support price is $.11 and resistance is $.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM shares will trade within this expected range on the day.